戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 iable immunodeficiency syndrome (a defect in antibody formation).
2 ogy), and participant incidence of denosumab antibody formation.
3 hile preventing rejection and donor-specific antibody formation.
4  diversity as does genetic recombination and antibody formation.
5 o study cellular and molecular mechanisms of antibody formation.
6  region of the PLA2R1 gene may contribute to antibody formation.
7 y Response Evaluation Criteria, and antidrug antibody formation.
8 ody after AMR therapy and the absence of new antibody formation.
9           No patient developed antigaliximab antibody formation.
10 cant association with de novo posttransplant antibody formation.
11 here was no evidence of host antitrastuzumab antibody formation.
12 related expression of hFIX without anti-hFIX antibody formation.
13 resulted in 500 ng/mL hFIX in plasma without antibody formation.
14  monitored for tumor response, toxicity, and antibody formation.
15 on therapy completely inhibited anti-hamster antibody formation.
16 ormalizes peripheral platelet counts without antibody formation.
17 e germinal centre reaction and high affinity antibody formation.
18 pCMV-LacZ did not inhibit IgE anti-ovalbumin antibody formation.
19           We found a high incidence of PRT/H antibody formation (29%) in patients undergoing cardiac
20    Immune tolerance was confirmed by lack of antibody formation after repeated challenges with cFVIII
21     Plasma concentrations of both agents and antibody formation against both agents were also assesse
22  a period of 17-18 days enable assessment of antibody formation against the human Tf component of the
23 e determined the prevalence of self-reactive antibody formation and its regulation in human B cells.
24                       At 3 months, anti-drug antibody formation and low adalimumab concentrations wer
25 s persistence correlated with poor anti-hAAT antibody formation and minimal hepatocyte toxicity.
26                                           No antibody formation and T-cell responses to FIX-R338L wer
27 B cell and macrophage reactions culminate in antibody formation and TGF-beta secretion, respectively,
28 thin donor grafts, diminished donor-specific antibody formation, and delayed rejection of subsequent
29 uman immunodeficiency virus (HIV) may impair antibody formation, and false-negative hepatitis C virus
30 g-term expression of FVIII, without apparent antibody formation, and improved the phenotype of hemoph
31 ng salivary bacterial burdens, corresponding antibody formation, and periodontitis severity than A. a
32  uncovered 5 suggestive loci for antinuclear antibody formation, consisting of 3 dominant NZB contrib
33 feron, and the incidences of anti-interferon antibody formation did not significantly differ among th
34 cient mice demonstrated enhanced T-dependent antibody formation especially of IgE isotype and allergi
35 ic systemic immune suppression of pathogenic antibody formation (immunoglobulin [Ig] 1/inhibitors, Ig
36 ll costimulatory signals for antifactor VIII antibody formation in a murine model of hemophilia A.
37 ant forms of Hb have been shown to stimulate antibody formation in a variety of animal species.
38  when aberrantly regulated, drive pathogenic antibody formation in autoimmunity and undergo neoplasti
39  address serious complications of inhibitory antibody formation in current replacement therapy, we cr
40 ntial utility to treat anti-FVIII inhibitory antibody formation in hemophilia A patients.
41 entified novel genetic markers of inhibitory antibody formation in hemophilia patients that may ultim
42    These data demonstrate increased anti-CCP antibody formation in HLA-DR4-positive patients with pol
43 AA activity in plasma and prevented anti-GAA antibody formation in immunocompetent GAA-knockout mice
44                   HA22-LR-8M does not induce antibody formation in mice when given repeatedly by intr
45 al element of the clonal selection theory of antibody formation in order to explain tolerance of self
46 individuals correlates with the frequency of antibody formation in patients with normal immune system
47 The stabilized oligomers were used to induce antibody formation in rabbits.
48             There was a marked difference in antibody formation in the two strains of mice; 100% of t
49 database was assessed for cases of antidonor antibody formation in tolerant animals over the last 20
50 ith respect to its poor biodegradability and antibody formation, including new evidence about preform
51                                   Inhibitory antibody formation is a major complication of factor VII
52 e free ("active") drug concentration and the antibody formation is critical for preclinical and clini
53 y all patients with HIT/T, it is unclear how antibody formation is initiated, why only a small subset
54                       These include impaired antibody formation; loss of delayed cutaneous hypersensi
55 ppressing cell-mediated immune responses and antibody formation, major factors in acute and chronic r
56 sinic:polycytidylic acid enhanced anti-FVIII antibody formation, MZ B-cell depletion continued to dis
57 d showed similar patterns of anti-adenovirus antibody formation, only Balb/c and C3H mice developed s
58 pressed therapeutic levels of FVIII, without antibody formation or other toxicities, for more than 3
59 e patients had no increased frequency of new antibody formation posttransplant.
60  recovery but that neutralizing anti-PIXY321 antibody formation suppressed the hematologic and bioche
61 h revealed domain contributions to secretory antibody formation, these results provide detailed model
62 priming of mice with pCMV-LacZ prevented IgE antibody formation to a subsequent i.p. beta-gal in alum
63 ministration of vectors may avoid inhibitory antibody formation to factor VIII (FVIII) by taking adva
64 tion of CD4(+)CD25(+)GITR(+) that suppresses antibody formation to FIX.
65 ctivity reaching 25% to 40% activity without antibody formation to FIX.
66 her genetic factors may increase the risk of antibody formation to functional F.IX.
67 as been stable for >1 year (ongoing) without antibody formation to the cFVII transgene.
68  depletion of CD4(+)CD25(+) T(regs) leads to antibody formation to the FIX transgene product after he
69 nsfusion on the breadth and magnitude of HLA antibody formation using current, sensitive, HLA-specifi
70 s that differ in size and/or zeta potential, antibody formation varies inversely with heparin concent
71                                 Anti-PIXY321 antibody formation was assessed by enzyme-linked immunos
72      The effect of neonatal gene transfer on antibody formation was determined using a retroviral vec
73                     After protein challenge, antibody formation was markedly reduced for animals that
74 mmune responsiveness to CEA, as reflected by antibody formation, was not detectable in transgenic mic
75 pression of canine G-CSF caused neutralizing antibody formation which precluded long-term increases i

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。